Monish Moyal, BSc, OMS-II: No relevant financial relationships with any proprietary interests.
Learning Objectives:
Describe the mechanisms of action of cabozantinib in glioblastoma, including its inhibition of MET, VEGFR2, and AXL signaling pathways, and their role in tumor angiogenesis, growth, and invasion.
Evaluate preclinical evidence of cabozantinib efficacy, including patient-derived xenograft (PDX) models, dose–response findings, and histological analyses of tumor vasculature and survival outcomes.
Identify potential biomarkers and resistance mechanisms that influence variability in GBM response to cabozantinib, and discuss strategies for patient selection.
Discuss the rationale for combination strategies, such as cabozantinib with temozolomide, radiotherapy, or immunotherapy, to overcome resistance and enhance therapeutic outcomes.
Assess the translational challenges and future directions in applying cabozantinib for GBM, including blood–brain barrier penetration, optimization of drug delivery, and integration into surgical and multidisciplinary care frameworks.
Summarize the key findings from clinical studies of cabozantinib in GBM and explain their practical implications for patient care and surgical decision-making.
